Primary and secondary endpoints
During the follow-up, eGFR (primary endpoint) did not show a
statistically significant worsening over the course of the study. The
baseline value was 88.10±26.47 ml/min/1.73m2 and
remained stable (83.25±29.27 ml/min/1.73m2; p=0.134)
until the end of the study at 36M. Values during follow-up are shown in
Table 2.
The secondary endpoint includes results based on the type of oral
antidiabetic drug (metformin, sulfonylureas, dipeptidyl peptidades-4
inhibitors [DPP-4i], and SGLT2i) that patients were taking. In this
case, we did not observe eGFR differences during the follow-up, except
in the insulin group. Patients using insulin had a worse GFR at 12M
(p=0.008) that those who did not (Table 3).